The Malaria drugs in development market research report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Malaria. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Malaria and features dormant and discontinued products.
GlobalData tracks 255 drugs in development for Malaria by 162 companies/universities/institutes. The top development phase for Malaria is preclinical with 96 drugs in that stage. The Malaria pipeline has 147 drugs in development by companies and 108 by universities/ institutes. Some of the companies in the Malaria pipeline products market are: Novartis, Eisai and GSK.
The key targets in the Malaria pipeline products market include Plasmodium falciparum Circumsporozoite Protein, Plasmodium falciparum Merozoite Surface Protein 1, and Plasmodium falciparum 25 kDa Ookinete Surface Antigen.
The key mechanisms of action in the Malaria pipeline product include Plasmodium falciparum Circumsporozoite Protein Inhibitor with six drugs in Phase II. The Malaria pipeline products include ten routes of administration with the top ROA being Oral and 16 key molecule types in the Malaria pipeline products market including Small Molecule, and Subunit Vaccine.
Malaria overview
Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea, and vomiting. Treatment includes anti-malarial medicines.
For a complete picture of Malaria’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
